Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus PROMETHACON.
CETIRIZINE HYDROCHLORIDE ALLERGY vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
5-10 mg orally once daily; maximum 10 mg/day.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Renal (80%) as inactive metabolites, 20% fecal via bile
Category A/B
Category C
Antihistamine
Antihistamine